146 related articles for article (PubMed ID: 25468141)
1. Biomarkers of glioblastoma multiforme.
Nicolaidis S
Metabolism; 2015 Mar; 64(3 Suppl 1):S22-7. PubMed ID: 25468141
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine in neurosurgery.
Nicolaidis S
Metabolism; 2013 Jan; 62 Suppl 1():S45-8. PubMed ID: 23018147
[TBL] [Abstract][Full Text] [Related]
4. Towards developing biomarkers for glioblastoma multiforme: a proteomics view.
Jayaram S; Gupta MK; Polisetty RV; Cho WC; Sirdeshmukh R
Expert Rev Proteomics; 2014 Oct; 11(5):621-39. PubMed ID: 25115191
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma biomarkers from bench to bedside: advances and challenges.
Farias-Eisner G; Bank AM; Hwang BY; Appelboom G; Piazza MA; Bruce SS; Sander Connolly E
Br J Neurosurg; 2012 Apr; 26(2):189-94. PubMed ID: 22176646
[TBL] [Abstract][Full Text] [Related]
7. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
9. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of DLX2 confers a poor prognosis in glioblastoma patients by inducing a proliferative phenotype.
Yan ZH; Bao ZS; Yan W; Liu YW; Zhang CB; Wang HJ; Feng Y; Wang YZ; Zhang W; You G; Zhang QG; Jiang T
Curr Mol Med; 2013 Mar; 13(3):438-45. PubMed ID: 23331016
[TBL] [Abstract][Full Text] [Related]
11. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
12. Individualized targeted therapy for glioblastoma: fact or fiction?
Weller M; Stupp R; Hegi M; Wick W
Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
[TBL] [Abstract][Full Text] [Related]
13. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
[TBL] [Abstract][Full Text] [Related]
14. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
Ruano Y; Mollejo M; Camacho FI; Rodríguez de Lope A; Fiaño C; Ribalta T; Martínez P; Hernández-Moneo JL; Meléndez B
Cancer; 2008 Apr; 112(7):1575-84. PubMed ID: 18260157
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients.
Oblinger JL; Pearl DK; Boardman CL; Saqr H; Prior TW; Scheithauer BW; Jenkins RB; Burger PC; Yates AJ
Neuropathol Appl Neurobiol; 2006 Aug; 32(4):410-8. PubMed ID: 16866986
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
17. Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme.
Kase M; Vardja M; Lipping A; Asser T; Jaal J
Radiother Oncol; 2011 Oct; 101(1):127-31. PubMed ID: 21775006
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical study of extracellular matrix proteins laminin, fibronectin and type IV collagen in paediatric glioblastoma multiforme.
Caffo M; Germanò A; Caruso G; Meli F; Galatioto S; Sciacca MP; Tomasello F
Acta Neurochir (Wien); 2004 Oct; 146(10):1113-8; discussion 1118. PubMed ID: 15309586
[TBL] [Abstract][Full Text] [Related]
19. [OMICS and biomarkers of glial tumors].
Idbaih A
Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
[TBL] [Abstract][Full Text] [Related]
20. IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals.
Ping Y; Zhang H; Deng Y; Wang L; Zhao H; Pang L; Fan H; Xu C; Li F; Zhang Y; Gong Y; Xiao Y; Li X
Mol Biosyst; 2014 Aug; 10(8):2031-42. PubMed ID: 24911613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
